EUVIMEDEUVIMED entdecken
Crossref

Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells

Jin Lei, Xue-Wei Cao, Peng-Fei Li, Jian Zhao iD, Fu-Jun Wang iD

FEBS Letters · 2024

DOI: 10.1002/1873-3468.15034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Letters, 2024. Verfasst von Jin Lei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology, East China University of Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Liver X Receptors, Triterpenes, B7-H1 Antigen, Saponins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Fonow Medicine Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most tumors are resistant to programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) checkpoint inhibitors, which may be due to impaired antigen presentation resulting from the downregulation of major histocompatibility complex class I (MHC‐I) expression on tumor cells. We observed that platycodin D (PD), polygalacin D, and platycodin D2, which are plant‐derived triterpenoid saponins, significantly reduced PD‐L1 levels. RNA sequencing and the PharmMapper database analysis identified liver X receptor β (LXR‐β) as a potential PD target. Further studies showed that PD reduces PD‐L1 levels by binding to LXR‐β and inhibiting LXR‐β activity. Coadministration of PD and nintedanib, known to upregulate MHC‐I expression, enhanced tumor recognition and killing by T cells. This study provides new insights into PD applications and mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver X ReceptorsTriterpenesB7-H1 AntigenSaponinsT-LymphocytesHumansAnimalsMiceCell Line, TumorIndoles

Stichwörter der Autor:innen

MHCPD‐L1cancer therapycholesterolimmunotherapyplatycodin D

Substanzen

Liver X ReceptorsTriterpenesB7-H1 AntigenSaponinsplatycodin DCD274 protein, humanIndoles

Autor:innen und Institutionen

  • Department of Applied Biology, East China University of Science and Technology, Shanghai, China.
  • ECUST-FONOW Joint Research Center for Innovative Medicines, East China University of Science and Technology, Shanghai, China.
  • New Drug R&D Center, Zhejiang Fonow Medicine Co., Ltd., Dongyang, China.
  • Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, China.

ORCID-Profile: Jian Zhao, Fu-Jun Wang

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Fonow Medicine Co., Ltd.

Zitieren

APA

Lei, J., Cao, X. W., Li, P. F., Zhao, J., & Wang, F. J. (2024). Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells. FEBS Letters. https://doi.org/10.1002/1873-3468.15034

Vancouver

Lei J, Cao XW, Li PF, Zhao J, Wang FJ. Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells. FEBS Letters. 2024. doi:10.1002/1873-3468.15034

BibTeX
@article{Lei2024,
  author = {Lei, Jin and Cao, Xue-Wei and Li, Peng-Fei and Zhao, Jian and Wang, Fu-Jun},
  title = {Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells},
  journal = {FEBS Letters},
  year = {2024},
  doi = {10.1002/1873-3468.15034}
}
Kostenlos starten →